

1 **Bleeding And Thrombosis In Patients With Out Of Hospital VT/VF Arrest Treated With**
2 **Extracorporeal Cardiopulmonary Resuscitation**

3
4 Alejandra Gutierrez MD^{1,2}, Rajat Kalra MBChB, MS^{1,2}, Kevin Y. Chang MD³, Marie E. Steiner
5 MD, MS^{4,5}, Alexandra M. Marquez MD, MSTR^{2,5}, Tamas Alexy MD, PhD^{1,2}, Andrea M. Elliott
6 MD^{1,2}, Meagan Nowariak BA⁶, Demetris Yannopoulos MD^{1,2}, Jason A Bartos MD, PhD^{1,2}

7
8 **Affiliations**

9 ¹ Cardiovascular Division, Department of Medicine, University of Minnesota School of
10 Medicine, Minneapolis, Minnesota

11 ²Center for Resuscitation Medicine, University of Minnesota School of Medicine, Minneapolis,
12 Minnesota

13 ³Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota

14 ⁴Division of Hematology and Oncology, Department of Pediatrics, University of Minnesota
15 School of Medicine, Minneapolis, Minnesota

16 ⁵Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Minnesota
17 School of Medicine, Minneapolis, Minnesota

18 ⁶University of Minnesota School of Medicine, Minneapolis, Minnesota

19 Short title: Bleeding and Thrombosis in eCPR

20 **Keywords:** eCPR, ECMO, resuscitation, cardiac arrest, bleeding, thrombosis, coagulopathy,
21 survival.

22
23 **Word count: 4598**

24 **Corresponding author**

25 Alejandra Gutierrez MD

26 Cardiovascular Division

27 University of Minnesota

28 420 Delaware Street SE

29 MMC 508

30 Minneapolis, MN 55455

31 Email: agb@umn.edu

32

33 **Abstract**

34 **Background:** Extracorporeal cardiopulmonary resuscitation (eCPR) improves outcomes after
35 out of hospital cardiac arrest (OHCA). However, bleeding and thrombosis are common
36 complications. The post cardiac arrest syndrome including trauma and altered hemostasis creates
37 challenges when balancing the risk of bleeding versus thrombosis. We aimed to describe the
38 incidence and predictors of bleeding and thrombosis and their association with in-hospital
39 mortality.

40 **Methods:** Consecutive patients presenting with refractory VT/VF OHCA between December
41 2015 and March 2022 who met criteria for eCPR initiation at our center were included. Patients
42 were anticoagulated with unfractionated heparin while on ECMO. Major bleeding was defined
43 by the extracorporeal life support organization's (ELSO) criteria as clinically significant bleed
44 associated with transfusion of ≥ 2 units of red blood cells in 24h or bleeding in a critical area.
45 Thrombosis was defined by clinical signs and symptoms and or imaging evidence of thrombi.
46 Adjusted analyses were done to seek out risk factors for bleeding and thrombosis and evaluate
47 their association with mortality.

48
49 **Results:** Major bleeding occurred in 135/200 patients (67.5%) with traumatic bleeding from
50 CPR in 73/200 (36.5%). Baseline demographics and arrest characteristics were similar between
51 groups. In multivariable regression analysis only fibrinogen was independently associated with
52 bleeding (aHR 0.98 per every 10mg/dl rise, 95% CI: 0.96-0.99). Patients who died had a higher
53 rate of bleeds per day (0.21 vs 0.03, $p < 0.001$) though bleeding was not significantly associated
54 with in-hospital death (aHR 0.81, 95% CI: 0.55-1.19). A thrombotic event occurred in 23.5%
55 (47/200). Venous thromboembolism (VTE) occurred in 11% (22/200) and arterial thrombi in
56 15.5% (31/200). Clinical characteristics were comparable between groups. In adjusted analyses,
57 antithrombin III level on admission (aHR 0.97, 95% CI: 0.94-0.99) and use of dual anti-platelet
58 therapy (DAPT) (aHR 0.31, 95% CI: 0.11-0.86) were associated with the incidence of
59 thrombosis. Thrombosis was not associated with in-hospital death (aHR 0.65, 95% CI: 0.42-
60 1.03).

61
62 **Conclusion:** Bleeding is a frequent complication of eCPR that is associated with decreased
63 fibrinogen levels on admission. Thrombosis is less common occurring in 24% of the cohort.
64 Neither bleeding nor thrombosis was significantly associated with in-hospital mortality.

65
66 **Word count 339**

67

68 Abbreviations

69

70 CPR- cardiopulmonary resuscitation

71 DAPT- Dual antiplatelet therapy

72 eCPR- Extracorporeal cardiopulmonary resuscitation

73 PCI- percutaneous coronary intervention

74 OHCA- Out-of-hospital cardiac arrest

75 VA-ECMO- Veno arterial extracorporeal membrane oxygenation

76 VT/VF-Ventricular tachycardia/Ventricular fibrillation

77

78 Clinical Perspective:

79 What is new?

- 80 • In this large single center study with a protocolized approach to anticoagulation for
- 81 patients with VT/VF OHCA bleeding as defined by ELSO major bleeding was common
- 82 occurring in 68% of the cohort while thrombosis was less frequent occurring in 24% with
- 83 the more than half of the events being arterial thrombi.
- 84 • Bleeding events are multifactorial including trauma from prolonged CPR, access site
- 85 bleeding, and mucosal bleeding.
- 86 • Neither bleeding nor thrombosis is associated with overall in-hospital mortality.

87

88 What are the Clinical implications?

- 89 • The high incidence of bleeding and low incidence of thrombosis with the current
- 90 approach to anticoagulation which often involves antithrombotic therapy reinforces the
- 91 need for a better method to risk stratify patients to better tailor anticoagulation strategies.
- 92 • The lack of association of bleeding and thrombotic events with mortality support a less
- 93 aggressive anticoagulation strategy to minimize bleeding.

94 Introduction

95 Extracorporeal cardiopulmonary resuscitation (eCPR) improves survival after out-of-hospital
96 cardiac arrest (OHCA)(1-5). Incidence of EMS-assessed OHCA is estimated to be 350,000 in
97 2015 per AHA with 7% surviving with a good neurologic outcome(6). Mortality after OHCA has
98 remained poor with further worsening during the COVID 19 pandemic(6). The ARREST trial
99 demonstrated that eCPR, including emergent cannulation with extracorporeal membrane
100 oxygenation (ECMO), improved the absolute survival to hospital discharge by 36% for patients
101 with OHCA due to ventricular tachycardia or ventricular fibrillation (VT/VF) as the presenting
102 rhythm(1). Anticoagulation management of patients presenting with VT/VF OHCA supported by
103 eCPR is challenging with competing thrombogenic insults and high bleeding risk due to trauma
104 from prolonged CPR and coagulopathy related to cardiac arrest and the ECMO circuit. Bleeding
105 is the most common complication of eCPR occurring in 8 to 70% of cases depending on the case
106 series and definition of bleeding used(2, 7, 8) while thrombotic rates are not well documented in
107 the literature.

108 The bleeding risk associated with eCPR is multifactorial and its quantification is difficult.
109 The contact of blood with artificial surfaces and the sheer stress of the mechanical circuit leads to
110 an acquired coagulopathy by activating the coagulation cascade. Therefore, patients are
111 anticoagulated to prevent thromboembolic events and oxygenator thrombosis(9). eCPR in the
112 setting of severe coronary artery disease presents further challenges as patients often require dual
113 antiplatelet therapy (DAPT) to protect the newly placed coronary stents (8, 10). Moreover, the
114 trauma associated with prolonged CPR and the inflammation and coagulopathy associated with
115 ischemia and reperfusion injury which hallmarks the post cardiac arrest syndrome enhances the
116 already heightened risk of bleeding and thrombosis(11). Data regarding the incidence and
117 predictors of bleeding and thrombosis as well as their impact on outcomes in VT/VF patients
118 treated with eCPR is lacking.

119 We aimed to describe the incidence, severity, and predictors of bleeding and thrombosis and
120 their association with in-hospital mortality.

121

122 Materials and Methods

123 2.1 Study population

124 Consecutive patients enrolled in the University of Minnesota (UMN) out-of-hospital
125 refractory VT/VF arrest protocol between December 2015 and March 2022 were eligible for
126 inclusion. Procedures were followed in accordance with the ethical standards of the IRB and in
127 accordance with the Helsinki Declaration of 1975. The study was reviewed and approved by the
128 Institutional Review Board (IRB) at the UMN (IRB #1703M11301). A waiver of informed
129 consent was granted given the research was retrospective involving no more than minimal risk.

130 The UMN protocol has been previously described (3, 8, 12-16). Briefly, patients were
131 screened by paramedics (EMS) to include adults 18-75 years of age, with a shockable presenting
132 rhythm and no return of spontaneous circulation (ROSC) after 3 shocks or shock-triggered
133 conversion to pulseless electrical activity or asystole, ongoing CPR with a Lund University
134 Cardiac Arrest System (LUCASTM), and an estimated transfer time to the closest cannulation site
135 of less than 30 minutes. At the cannulation site patients were assessed for the presence of the

136 following physiologic criteria: 1) end-tidal CO₂ >10mmHg; 2) PaO₂ ≥50mmHg; 3) lactic acid
137 ≤18mmol/L. Patients meeting the physiologic criteria with ongoing arrest and those who
138 obtained ROSC but were unstable with refractory cardiogenic shock and hypotension despite
139 other interventions such as intra-aortic balloon pump placement (IABP; Maquet Cardiovascular,
140 Wayne, NJ, U.S.A.), vasopressors or inotropes underwent ultrasound-guided and fluoroscopy
141 assisted percutaneous V-A ECMO cannulation. Arterial (15-17Fr) and venous (25Fr) cannulas
142 were typically inserted in the ipsilateral common femoral artery and femoral vein, though
143 contralateral cannulation was used as needed. An antegrade perfusion cannula was inserted into
144 the superficial femoral artery ipsilateral to the arterial ECMO cannula to perfuse the distal lower
145 extremity. Per protocol, a heparin bolus was administered at the time of cannulation(17). All
146 patients underwent coronary angiography with percutaneous coronary intervention (PCI) as
147 indicated following cannulation. An intravascular cooling catheter was placed for targeted
148 temperature management with a goal temperature of 34 C for 24 hours unless uncontrolled
149 bleeding necessitated a higher temperature target. The addition of an IABP was left to the
150 discretion of the interventional cardiologist to maintain coronary perfusion in the setting of
151 severe coronary artery disease or lack of cardiac pulsatility defined as an arterial pulse pressure
152 of less than 10 mmHg after initiation of V-A ECMO and PCI. All patients had non-contrast
153 computerized tomography (CT) of their head, chest, abdomen and pelvis upon admission given
154 the high prevalence of trauma associated with CPR(2, 18).

155 Patients were admitted to a centralized cardiac intensive care unit (CICU). A continuous
156 unfractionated heparin infusion was administered targeting an ACT goal of 180-200sec.
157 Anticoagulation targets were adjusted by the treating physician in patients with uncontrolled
158 bleeding. A heparin infusion of 2 U/mL in normal saline was administered at 3mL/hr
159 continuously through the antegrade perfusion cannula to maintain its patency. This infusion
160 continued regardless of the presence of bleeding.

161 *2.2 Study definitions and outcome variables*

162 Data was collected by retrospective chart review of medical records. The primary
163 outcome was in-hospital mortality. Secondary outcomes were major bleeding and thrombosis.
164 Major bleeding was defined by the ELSO criteria including clinically overt bleeding associated
165 with a hemoglobin fall of ≥2g/dl or ≥2 units of red blood cells transfused during a 24 hour
166 period(17). This included bleeding in a critical area defined as bleeding occurring in the
167 retroperitoneum, pulmonary, central nervous system, or requiring surgical intervention regardless
168 of the decline of hemoglobin or units of blood transfused. Given initial volume expansion,
169 hemolysis, intra-procedural blood loss, and frequent lab draws, it is common for patients to drop
170 their hemoglobin values significantly with successful V-A ECMO resuscitation after cardiac
171 arrest. Therefore, we scrutinized the medical records to identify clinical signs of bleeding noted
172 by the treatment team or present on imaging associated with transfusions or hemoglobin drop to
173 determine major bleeding events. A declining hemoglobin level without clinical bleeding was
174 not considered a bleeding event.

175 The presence of thrombosis was determined by imaging studies with corresponding
176 clinical correlates of venous or arterial thrombi. This was further classified into: 1 arterial
177 thrombi including stroke as evidenced by imaging, thrombi in the left atrium, left ventricle,
178 aortic valve or other arterial bed such as the superior mesenteric artery and oxygenator

179 thrombosis requiring exchange of the oxygenator and 2. Venous thrombi including DVT and
180 IVC thrombosis, right atrial thrombi or pulmonary embolism.

181 The first arterial blood gas collected just prior to ECMO cannulation was used to
182 establish initial hemoglobin level. Other laboratory parameters were obtained from the first
183 complete set of blood work performed on arrival to the CICU.

184 2.3 Statistical Analysis

185 Continuous variables were represented as means with standard deviations and compared
186 using the t-test or analysis of variance (ANOVA) tests. Non-normal continuous variables were
187 represented as medians with interquartile ranges and compared with the Wilcoxon Rank-Sum test.
188 Categorical variables were represented as counts with proportions and compared with the chi-
189 squared test.

190
191 To identify predictors of major bleeding, the association of age, CPR time, baseline use of
192 anticoagulation, use of DAPT during the admission, INR, fibrinogen, antithrombin III and
193 platelet count were first evaluated in unadjusted analyses. These factors were selected due to the
194 established data suggesting their association with bleeding and thrombosis. Predictors that were
195 significant at $p < 0.20$ in unadjusted analyses were included via stepwise selection in an adjusted
196 (multivariable) Cox proportional hazards model to determine which factors remained significant
197 predictors of major bleeding events. The same method was used to determine which clinical
198 factors were significant predictors of thrombotic events.

199
200 Cox multivariable regression analyses were done to account for the effect of clinically
201 important covariates in the association between major bleeding and thrombosis with in-hospital
202 death. Age, sex, CPR time, use of DAPT were chosen *a priori* as covariates in Cox multivariable
203 regression analyses. These variables were chosen due to their acknowledged associations with
204 bleeding and thrombotic events. The proportional hazard assumption was checked using
205 Schoenfeld's residuals. To overcome immortal time bias for VTE, landmark analysis was
206 performed using 5 days as the landmark time for this survival analysis(19). For the survival
207 analyses that assessed the association of major bleeding events with in-hospital death, major
208 thrombosis was also included as a covariate in the multivariable analyses, due to the tendency of
209 thrombosis to affect clinical anticoagulation management. Similarly, major bleeding events were
210 included as a covariate in the survival analyses that assessed the association of thrombosis with
211 in-hospital death.

212
213 In-hospital death may be a competing event for the occurrence of major bleeding events
214 and/or thrombosis during treatment with VA-ECMO. Thus, competing risk analyses were
215 performed to evaluate factors that may be associated with major bleeding events and thrombosis,
216 respectively. The cumulative incidence of major bleeding events and thrombosis was estimated
217 using Gray's test. In-hospital death due to causes other than bleeding events or thrombosis were
218 the competing events. The results were represented as sub-hazard ratios (sHRs) with 95%
219 confidence intervals. The Fine-Gray model was used to perform multivariable regression. The
220 level of statistical significance was set at < 0.05 for all analyses. The analyses were done with
221 IBM SPSS v28 (Chicago, IL, U.S.A.) and StataMP 17.0 (College Station, TX, U.S.A.).

222

223 Results

224 3.1 Study population

225 A total of 260 patients presented within criteria with a VT/VF cardiac arrest and achieved
226 an organized rhythm at the end of the cardiac catheterization case. 23% of patients achieved
227 stable ROSC and did not require V-A ECMO to stabilize their cardiogenic shock and were
228 therefore excluded from this analysis. The final study population consisted of 200 patients.

229 Baseline characteristics are shown in **Table 1**. The majority of the cohort was male
230 (81%) with a mean age of 57 (12.2) years. Comorbid conditions included coronary artery disease
231 in 26% (52/200), congestive heart failure (CHF) in 12.5% (25/200), diabetes in 24.5% (49/200)
232 and hypertension in 35.5% (71/200). Prior to admission medications included: a direct oral
233 anticoagulant in 6/200 (3%), a vitamin K antagonist in 4/200 (2%), aspirin in 29/200(14.5%) and
234 a P2Y12 inhibitor in 3/200 (1.5%). The average CPR time from 911 call or identified arrest by
235 EMS to V-A ECMO initiation was 62± 19 minutes. An IABP was placed in 71% (142/200) of
236 the cohort. Revascularization was performed in 121/200 (60.5%) of patients and DAPT was
237 given to 62.0% (124/200) of the cohort.

238 The hemoglobin on initial presentation to the emergency department or catheterization
239 lab was 12.6±2.6 g/dl. Other lab parameters were obtained at the time of arrival to the CICU.
240 Most blood tests were above normal limits (**Figure 1**) including: ALT (187±199 U/L), AST
241 (372±410 U/L), INR(2.0±0.9), ACT (224±63), PTT (195±72sec) and D-dimer(16±7Ug/mL).
242 Antithrombin III levels were often below the normal range of our laboratory (>85%) with an
243 average of 59.6% ± 16.9 while the average fibrinogen of our cohort was within normal limits at
244 234±109 mg/dL.

245 3.2 Predictors of Bleeding

246 Major bleeding was common occurring in 135/200 patients (67.5%). There was more
247 than one site of bleeding in 91/200 (45.5%) patients. Minor bleeding which did not meet criteria
248 for ELSO major bleeding occurred in 21/200(10.5%) of patients and there was no clinical
249 evidence of bleeding in 44/200 (22%) patients. Details regarding major bleeding site are shown
250 in **Figure2A**. The most common site of major bleeding was access site bleeding. This was
251 present in 106/200 (53.0%) with 6 patients requiring a surgical intervention to repair this.
252 Intracranial bleeding (ICH) occurred in 10/200 (5.0%) including 3 cases of subarachnoid
253 hemorrhage, 2 intraventricular hemorrhages, and 5 intraparenchymal hemorrhages. The median
254 day of diagnosis of ICH was 3 (1,7) days. CPR-related trauma was frequent, occurring in 73/200
255 (36.5%) of the cohort including mediastinal hematoma in 51/200(26%), 14/200 (7%) with
256 pericardial bleeding, 11% (22/200) with a hemothorax and 7% (14/200) intraperitoneal bleeding.
257 Gastrointestinal bleeding was clinically diagnosed in 33/200 (16.5%) patients. Most cases were
258 managed medically with only 6/200 cases (4.7%) undergoing upper endoscopy. The majority of
259 bleeding events (92%) happened while the patients were on V-A ECMO. The first major
260 bleeding event was frequently within the first days of hospitalization, with a median time from
261 admission to bleeding of 1 (0,2) day with 50% of patients bleeding on day 0-1 of admission and
262 74% of all bleeding events occurring before the third day of the hospitalization (**Figure 2B**).

263 Baseline comorbidities were comparable between those who had major bleeding and
264 those without major bleeding (**Table 1**). In unadjusted analysis, those with a bleeding event had

265 a lower hemoglobin (12.3 vs 13.1g/dL; $p=0.05$), platelets (179 vs 200 x 10³/uL, $p=0.04$),
266 fibrinogen (218 vs 266 mg/dL, $p=0.004$), and antithrombin III levels (57 vs 65%, $p<0.001$) on
267 admission (**Figure 1**). Our patients had an average D-dimer of 15.9(7.2) vs 15.2(7.0) ug/mL for
268 bleeding and non-bleeding patients respectively with a normal for our laboratory being 0.0-
269 0.5ug/mL and no significant difference among groups ($p=0.52$).

270 Use of procedural anticoagulation and antiplatelet medications were not associated with
271 bleeds. The use of iib/iiia inhibitors and cangrelor was uncommon (6/200(3.0%) and
272 16/200(8.0%), respectively). The average dose of heparin given for ECMO cannulation and rate
273 of PCI was not significantly different between groups.

274 In unadjusted analyses age, antithrombin III, and fibrinogen met the prespecified $p < 0.20$
275 threshold for inclusion in the adjusted model. In adjusted analyses, only fibrinogen was
276 associated with incident major bleeding events with every 10 unit rise in fibrinogen associated
277 with 0.98 times the hazard of major bleeding (HR 0.98, 95% CI: 0.95-0.99) (**Central Figure**).
278 The risk of bleeding seemed to heighten with fibrinogen levels below 300mg/dL (with 47.7% of
279 patients having a major bleed in those with a fibrinogen > 300mg/dL vs 72.8% in those with a
280 fibrinogen <300mg/dL, $p=0.003$) (**Figure 2C**).

281

282 *3.3 Outcomes associated with bleeding*

283 In unadjusted analyses, the occurrence of a major bleeding event was not significantly
284 associated with in-hospital death. Similarly, after adjustment for clinically relevant factors,
285 having an ELSO major bleeding event was not associated with in-hospital death (aHR 0.81, 95%
286 CI: 0.55-1.19).

287 Hospital course and outcomes are shown in **Table 2**. In unadjusted analysis, major
288 bleeding was associated with higher transfusion needs with patients who had a bleeding event
289 receiving a median of 7(4,12) units of red blood cells, 2(0,5) units of platelets and 1(0,3) unit
290 of fresh frozen plasma. Patients who had a bleeding event had similar rates of renal replacement
291 therapy(30.4 vs 21.5%; $p=0.25$), extubation (29.6 v 20.0%; $p=0.20$) and successful V-A ECMO
292 decannulation (48.1 vs 32.3%; $p=0.19$). For those patients who survived to extubation, the length
293 of mechanical ventilation was longer in patients who had a major bleeding event (9 vs 6 days,
294 $p=0.05$). The median length of hospital stay was 8 (2,21) days. Having a bleeding event was
295 associated with a longer length of hospitalization with a median of 10(3,22) compared to 4(2,14)
296 ($p=0.01$)days of admission.

297 In the adjusted competing risks analyses, age (sHR 1.01, 95% CI: 0.99-1.03), sex (sHR
298 0.75, 95% CI:0.44-1.27), CPR time (sHR 1.00, 95% CI: 0.99-1.01), use of DAPT during the
299 hospitalization (sHR: 0.96, 95% CI: 0.62-1.49), were not associated with major bleeding or all-
300 cause in-hospital mortality.

301

302 *3.5 Thrombotic events*

303 Arterial or venous thrombotic events were identified in 23.5% (47/200) patients. The sites
304 of thrombi are shown in **Figure 3A**. Venous thromboembolism including deep vein thrombosis
305 (DVT), right atrial thrombi and pulmonary embolism (PE) occurred in 22/200 (11.0%). Arterial
306 thromboembolism was seen in 31/200 (15.5%) with 6 patients experiencing both arterial and

307 venous thrombi during their hospitalization. Oxygenator thrombosis requiring exchange of the
308 membrane was uncommon, occurring in 1.5% of the cohort(3/200). Two of these occurred the
309 day of admission soon after cannulation and the other one occurred 12 days after cannulation.
310 Despite continuous anticoagulation infusion through the reperfusion cannula, problems with
311 thrombus formation in the tubing or catheter occurred in 5 patients (2.5%). Two other patients
312 (1%) had lower limb ischemia requiring thrombectomy to salvage the limb. Thrombosis occurred
313 at a median of 5(1,12) days from the day of admission. Arterial thrombi presented earlier (2 [1,6]
314 days) compared to VTE events (12 days [9,16]) **Figure 3B**.

315 There were no differences in baseline characteristics, comorbidities or arrest
316 characteristics in the groups with and without thrombosis (**Table 1**). Those who had a thrombotic
317 event had a higher fibrinogen level (264 vs 225, $p=0.03$) and a lower ALT (141 vs 202, $p=U/L$)
318 compared to those who did not have a thrombotic event (**Figure 1**). Treatment characteristics of
319 patients with and without thrombosis are shown in **Table 3**. The use of an IABP was not
320 associated with increased thrombotic events. A thrombus in the inferior vena cava was detected
321 in 6/300 (3.0%) accounting for 6/22 (27%) of all the deep venous thromboembolisms. Length of
322 V-A ECMO cannulation was associated with a longer time on V-A ECMO predominantly due to
323 longer runs in patients with arterial thrombi but was not associated with the rate of VTE (**Table**
324 **3**). In the univariate analyses, age, CPR time, baseline use of anticoagulation, DAPT
325 administration, antithrombin III, and platelet count met the pre specified $p < 0.20$ threshold for
326 inclusion in the adjusted model. In the adjusted analyses, a higher level of antithrombin III (aHR
327 0.97, 95% CI: 0.94-0.99) and use of DAPT (aHR 0.31, 95% CI: 0.11-0.86) were associated with
328 a reduced incidence of thrombosis (**Central Figure**).

329

330 *3.6 Outcomes associated with thrombosis*

331 Patients who had a thrombotic event had a higher number of transfusions of red blood
332 cells and platelets (7 versus 4 units; $p=0.01$ and 2 versus 1 units; $p=0.005$ respectively) (**Table**
333 **3**). There was no significant difference in terms of renal replacement therapy or rates of
334 extubation. However, the length of stay was significantly longer for those who had a thrombotic
335 event.

336 In the unadjusted analyses, the occurrence of a thrombotic event was not associated with
337 in hospital death (**Table 3**). After adjustment for age, sex, CPR time, use of DAPT and the
338 occurrence of major bleeding, the occurrence of thrombosis was not associated with in-hospital
339 death (aHR 0.65, 95% CI: 0.42-1.03). Adjustment for competing risk of death also negated the
340 difference observed in the unadjusted analysis. When stratified by type of thrombosis, VTE was
341 associated with in hospital mortality in unadjusted (**Table 3**) and adjusted analysis (aHR 0.22,
342 95% CI 0.09-0.60). The rate of VTE was associated with the length of stay with a rate of 0.01+/-
343 0.023 per day for those who survived compared to 0.003 +/-0.015 for those who died ($p=0.008$).
344 Each additional day of hospitalization was associated with an OR of 1.05 of VTE (95% CI: 1.0-
345 1.1, $p<0.001$) making it very sensitive to survival bias. In a landmark analysis, excluding patients
346 who died before the first 5 days of admission (none of whom had a VTE), VTE was no longer
347 associated with in hospital mortality (HR 0.44, 95% CI: 0.17-1.12).

348

349 Arterial site thrombosis was not associated with in hospital death in unadjusted (**Table 3**)
350 or adjusted analysis (aHR 1.2, 95% CI 0.73-1.94). In the adjusted competing risks analyses, only
351 age was associated with increased arterial site thrombosis (sHR 1.04, 95% CI 1.00-1.09).

352 353 **Discussion**

354 In this large observational single center study, we report the incidence and risk factors
355 associated with bleeding and thrombosis and their association with in-hospital mortality. Major
356 bleeding as defined by ELSO is a common complication of eCPR, affecting 67.5% of our cohort.
357 In multivariable analysis, the only risk factor associated with bleeding was decreasing levels of
358 fibrinogen. Thrombosis was less common than bleeding, occurring in 23.5% of patients with
359 11.0% of patients having a VTE and 15.5% an arterial thrombi. A higher level of antithrombin
360 III on admission and the administration of DAPT was associated with decreased thrombotic risk.
361 Neither bleeding nor thrombosis was associated with in-hospital mortality when results were
362 adjusted for clinically significant factors.

363 Reported rates of bleeding in the eCPR population vary widely(5, 20-25), but are higher
364 than those of other types of ECMO including V-A ECMO for other cardiac indications (21, 25)
365 or V-V ECMO (21). The heightened risk of bleeding is thought to be related to trauma from
366 prolonged CPR, hypothermia, and coagulopathy associated with the post cardiac arrest
367 syndrome(5, 11, 22). In our cohort, we found an incidence of intracranial hemorrhage of 5%
368 which is similar to that reported in other eCPR cohorts (4.3-5.6%)(21, 23), while 67.5% of
369 patients had major bleeding events. Although elevated, this is concordant with other eCPR
370 cohorts, including the study by Otani et al published in 2018 which reported a 70% (71/233)
371 bleeding rate(22). In their study, major bleeding was assessed by BARC (Bleeding Academic
372 Research Consortium) criteria defined as Type 3 or higher correlating to overt bleeding plus a
373 hemoglobin drop of ≥ 3 g/dL within 24 h of hospital admission(22). Similarly, the CHEER study
374 had a bleeding rate of 70% (18/26) though they do not specify how they defined this outcome(5).
375 However other studies of eCPR patients quote lower bleeding rates including: 38% as defined by
376 the BARC type 3 or higher (20), 39% assessed by BARC type 3b or higher(24), 26% per ELSO
377 criteria in the ELSO registry(25), and 20-22% without a clear definition of major bleeding(23,
378 26). The discrepancy is likely due to the various definitions of bleeding, with ELSO-defined
379 major bleeding being a more sensitive criteria including a drop of ≥ 2 g/dl/24h(26).

380 In unadjusted analysis, decreased levels of fibrinogen, antithrombin III and platelet count
381 were associated with increased risk of major bleeding. Prior studies on eCPR patients suggest
382 that hyperfibrinolysis may increase bleeding risk. In a study including 133 patients, higher D-
383 dimer level on admission (18.8ug/mL vs 6.7,ug/mL) was associated with major bleeding(22)..
384 We did not find significant associations between initial D-dimer and bleeding, but the D-dimer
385 levels of our cohort were very elevated (15.7 ± 0.5 ug/mL (normal for our laboratory: 0.0-
386 0.5ug/mL) and frequently reported as >20 ug/mL. This may have led to an underestimation of
387 the actual D-dimer levels in bleeding patients and may explain the disparate findings. However,
388 markers of coagulation factor consumption including low fibrinogen and low antithrombin III
389 were associated with bleeding. In adjusted analysis, decreased level of fibrinogen was the only
390 variable associated with increased bleeding risk. Another study including all V-A ECMO
391 patients identified fibrinogen among other factors to be predictive of bleeding (25). Low platelet
392 count, elevated D-dimer, and low fibrinogen has been observed in other eCPR populations with
393 an elevated disseminated coagulation score (DIC) score being associated with mortality(24, 27).

394 These studies excluded patients on DAPT whereas we had a significant proportion of patients on
395 DAPT and found a persistent association with markers of consumption and increased bleeding
396 risk.

397 Major bleeding increased in-hospital morbidity but was not associated with increased
398 mortality. The lack of association with in-hospital mortality diverges from some published
399 ECMO studies where bleeding has been associated with increased mortality(9, 21, 28). In
400 contrast to our data these studies included veno-venous and veno-arterial ECMO support(9, 21,
401 28) and pediatric and adult patients(9, 21). Further, it is possible that bleeding as defined by the
402 criteria for ELSO major bleeding is an insensitive marker of major events. However, other
403 studies have reported a lack of association between bleeding and in hospital death. In an
404 unadjusted analysis utilizing BARC type 3 or higher by Otani et al, the rates of bleeding were
405 similar in survivors and non-survivors treated with eCPR (46v33%, p=0.44). Similarly in a study
406 by Sahli et al including all-comers requiring ECMO support, development of bleeding
407 complications during ECMO was not an independent predictor of mortality though they did not
408 provide their definition of bleeding(23). Major bleeding was associated with increased
409 transfusion needs in this study in agreement with prior reports in the literature (9, 21, 23, 25) and
410 with longer time on mechanical ventilation.

411 Thrombotic complications are sparsely reported in the eCPR literature. We found a rate
412 of 22.5% which is similar to that published in another study including eCPR patients with a rate
413 of thrombosis of 21%(20), but higher than the 7% reported in a recent meta-analysis(26). The
414 risk of limb ischemia in the literature is around 16-24%(20, 26) whereas we had a much lower
415 rate of 1%. We routinely place antegrade perfusion catheters at the time of cannulation and
416 infuse heparin through that catheter. Further, our patients were uniformly eCPR patients with an
417 anticoagulation strategy that utilized an unfractionated heparin infusion targeting an ACT of 180-
418 200 sec. This is not a universal practice and may account for these differences(26). In our study,
419 predictors of thrombosis included lower levels of antithrombin III and patients without DAPT
420 administration. Data regarding risk factors for thrombosis is lacking. In a meta-analysis including
421 all types of ECMO, the anticoagulation strategy was not significantly associated with thrombotic
422 risk though the use of antiplatelet therapy was not reported(26).

423 In this cohort, thrombosis was not associated with increased mortality. Consistent with
424 other eCPR(20) and general ECMO (26) literature, we did not find any association between
425 survival and thrombosis(20). Thrombotic complications of eCPR include arterial and venous
426 thrombi and their pathophysiology differs significantly. Arterial thrombi typically present in the
427 first few days of admission while patients are highly reliant on the ECMO circuit and the ejection
428 fraction is frequently limited (16). The association of VTE with in-hospital mortality is likely
429 due to immortal time bias, with a rate of thrombosis per day of 0.01 +/- 0.02 for those who
430 survived vs 0.003+/- 0.02 for those who died. VTE is highly dependent on length of hospital stay
431 as has been shown in numerous cohorts including our data where the risk of VTE increased by
432 5% per each additional day of hospitalization(29, 30). A landmark analysis was performed to
433 overcome this important survival bias. In a study including routine ultrasound evaluation for
434 VTE post decannulation, DVT was found in 15/30 (50%) of those who survived to decannulation
435 where V-V ECLS and length of cannulation were the only predictors of VTE(31). In our cohort
436 the length of VA ECMO cannulation was not associated with the rate of VTE. Our rate of DVT
437 was significantly lower however, our cohort did not include V-V ECMO, and we only performed
438 ultrasounds when clinically indicated. Despite the underreported rate of thrombosis eCPR

439 patients are anticoagulated aggressively with more than half of them receiving antiplatelet
440 therapy in addition to heparin given the burden of acute coronary syndrome as the cause of
441 VT/VF arrest. Given the high rate of bleeding and low thrombotic risk in our eCPR population,
442 further research should evaluate anticoagulation strategies to find the optimal approach that
443 minimizes risk of bleeding without increasing thrombotic sequelae (26).

444 Given the retrospective nature of the study, some limitations are inevitable. While this
445 represents one of the largest single center cohorts published, its small size may limit
446 discrimination of small differences between groups. Despite performing adjusted analyses, we
447 cannot account for potential confounding from variables that were not included in the model.
448 The study was observational and change in anticoagulation management in response to bleeding,
449 thrombotic events, or lab values was not protocolized or mandated and was not included in the
450 analysis. Finally, despite using survival analysis and competing risk analysis, survival bias is
451 unavoidable. Patients who die are no longer able to experience a bleeding or thrombotic event
452 therefore our results should be interpreted with caution.

453

454 **Conclusions**

455 In this large study of eCPR patients, 67.5 % of patients experienced major bleeding as defined by
456 ELSO, while 23% of our cohort experienced thrombosis. Lower fibrinogen was associated with
457 increased bleeding risk while the use of DAPT and lower antithrombin III levels on admission
458 was associated with decreased thrombotic risk. Major bleeding was not associated with in-
459 hospital mortality, but both thrombosis and major bleeding were associated with in-hospital
460 morbidity with higher transfusion needs and longer mechanical ventilation days for those who
461 bled. There is a need to assess optimal anticoagulation and antiplatelet regimens that minimize
462 bleeding risk without increasing thrombotic consequences.

463 **Disclosure statement:** The authors report no financial relationships or conflicts of interest
464 regarding the content herein as well as no other relevant relationships to industry.

465

466

467

468 **References**

- 469 1. Yannopoulos D, Bartos J, Raveendran G, Walser E, Connett J, Murray TA, et al. Advanced
470 reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular
471 fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. *Lancet*.
472 2020;396(10265):1807-16.
- 473 2. Bartos JA, Carlson K, Carlson C, Raveendran G, John R, Aufderheide TP, et al. Surviving refractory
474 out-of-hospital ventricular fibrillation cardiac arrest: Critical care and extracorporeal membrane
475 oxygenation management. *Resuscitation*. 2018;132:47-55.
- 476 3. Bartos JA, Frascione RJ, Conterato M, Wesley K, Lick C, Sipprell K, et al. The Minnesota mobile
477 extracorporeal cardiopulmonary resuscitation consortium for treatment of out-of-hospital refractory
478 ventricular fibrillation: Program description, performance, and outcomes. *EclinicalMedicine*. 2020;29-
479 30:100632.
- 480 4. Bartos JA, Grunau B, Carlson C, Duval S, Ripeckyj A, Kalra R, et al. Improved Survival With
481 Extracorporeal Cardiopulmonary Resuscitation Despite Progressive Metabolic Derangement Associated
482 With Prolonged Resuscitation. *Circulation*. 2020;141(11):877-86.
- 483 5. Stub D, Bernard S, Pellegrino V, Smith K, Walker T, Sheldrake J, et al. Refractory cardiac arrest
484 treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). *Resuscitation*.
485 2015;86:88-94.
- 486 6. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and
487 Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*.
488 2022;145(8):e153-e639.
- 489 7. Inoue A, Hifumi T, Sakamoto T, Kuroda Y. Extracorporeal Cardiopulmonary Resuscitation for Out-
490 of-Hospital Cardiac Arrest in Adult Patients. *J Am Heart Assoc*. 2020;9(7):e015291.
- 491 8. Yannopoulos D, Bartos JA, Martin C, Raveendran G, Missov E, Conterato M, et al. Minnesota
492 Resuscitation Consortium's Advanced Perfusion and Reperfusion Cardiac Life Support Strategy for Out-
493 of-Hospital Refractory Ventricular Fibrillation. *J Am Heart Assoc*. 2016;5(6).
- 494 9. Mazzeffi M, Greenwood J, Tanaka K, Menaker J, Rector R, Herr D, et al. Bleeding, Transfusion,
495 and Mortality on Extracorporeal Life Support: ECLS Working Group on Thrombosis and Hemostasis. *Ann*
496 *Thorac Surg*. 2016;101(2):682-9.
- 497 10. Yannopoulos D, Bartos JA, Raveendran G, Conterato M, Frascione RJ, Trembley A, et al. Coronary
498 Artery Disease in Patients With Out-of-Hospital Refractory Ventricular Fibrillation Cardiac Arrest. *Journal*
499 *of the American College of Cardiology*. 2017;70(9):1109-17.
- 500 11. Wada T. Coagulofibrinolytic Changes in Patients with Post-cardiac Arrest Syndrome. *Front Med*
501 *(Lausanne)*. 2017;4:156.
- 502 12. Yannopoulos D, Bartos JA, Aufderheide TP, Callaway CW, Deo R, Garcia S, et al. The Evolving
503 Role of the Cardiac Catheterization Laboratory in the Management of Patients With Out-of-Hospital
504 Cardiac Arrest: A Scientific Statement From the American Heart Association. *Circulation*.
505 2019;139(12):e530-e52.
- 506 13. Gutierrez A CC, Kalra R, Elliott AM, Yannopoulos D, Bartos JA. Outcomes associated with delayed
507 enteral feeding after cardiac arrest treated with veno-arterial extracorporeal membrane oxygenation
508 and targeted temperature management. . *Resuscitation*. 2021;164:20-6.
- 509 14. Bartos JA, Clare Agdamag A, Kalra R, Nutting L, Frascione RJ, Burnett A, et al. Supraglottic airway
510 devices are associated with asphyxial physiology after prolonged CPR in patients with refractory Out-of-
511 Hospital cardiac arrest presenting for extracorporeal cardiopulmonary resuscitation. *Resuscitation*.
512 2023;186:109769.

- 513 15. Gutierrez A, Kalra R, Elliott AM, Marquez A, Yannopoulos D, Bartos JA. Acute lung injury and
514 recovery in patients with refractory VT/VF cardiac arrest treated with prolonged CPR and veno-arterial
515 extracorporeal membrane oxygenation. *Resuscitation*. 2023;182:109651.
- 516 16. Kalra R, Bartos JA, Kosmopoulos M, Carlson C, John R, Shaffer A, et al. Echocardiographic
517 evaluation of cardiac recovery after refractory out-of-hospital cardiac arrest. *Resuscitation*.
518 2020;154:38-46.
- 519 17. ELSO anticoagulation guideline: 2014 The Extracorporeal Life Support Organization (ELSO) Ann
520 Arbor, MI, USA [Available from: [https://www.else.org/Portals/0/Files/elseanticoagulationguideline8-
521 2014-table-contents.pdf](https://www.else.org/Portals/0/Files/elseanticoagulationguideline8-2014-table-contents.pdf).
- 522 18. Richardson ASC, Tonna JE, Nanjaya V, Nixon P, Abrams DC, Raman L, et al. Extracorporeal
523 Cardiopulmonary Resuscitation in Adults. Interim Guideline Consensus Statement From the
524 Extracorporeal Life Support Organization. *ASAIO J*. 2021;67(3):221-8.
- 525 19. Morgan CJ. Landmark analysis: A primer. *J Nucl Cardiol*. 2019;26(2):391-3.
- 526 20. Dennis M, McCanny P, D'Souza M, Forrest P, Burns B, Lowe DA, et al. Extracorporeal
527 cardiopulmonary resuscitation for refractory cardiac arrest: A multicentre experience. *Int J Cardiol*.
528 2017;231:131-6.
- 529 21. Li C, Cai T, Xie H, Wang L, Yang F, Du Z, et al. Risk factors and outcomes for patients with
530 bleeding complications receiving extracorporeal membrane oxygenation: An analysis of the Chinese
531 Extracorporeal Life Support Registry. *Artif Organs*. 2022.
- 532 22. Otani T, Sawano H, Natsukawa T, Matsuoka R, Nakashima T, Takahagi M, et al. D-dimer predicts
533 bleeding complication in out-of-hospital cardiac arrest resuscitated with ECMO. *Am J Emerg Med*.
534 2018;36(6):1003-8.
- 535 23. Sahli SD, Kaserer A, Braun J, Halbe M, Dahlem Y, Spahn MA, et al. Predictors associated with
536 mortality of extracorporeal life support therapy for acute heart failure: single-center experience with
537 679 patients. *J Thorac Dis*. 2022;14(6):1960-71.
- 538 24. Mecklenburg A, Stamm J, Angriman F, Del Sorbo L, Fan E, Soeffker G, et al. Impact of therapeutic
539 hypothermia on bleeding events in adult patients treated with extracorporeal life support peri-cardiac
540 arrest. *J Crit Care*. 2021;62:12-8.
- 541 25. Willers A, Swol J, van Kuijk SMJ, Buscher H, McQuilten Z, Ten Cate H, et al. HEROES V-A-
542 HEmoRrhagic cOmplications in veno-arterial Extracorporeal life Support-Development and internal
543 validation of a multivariable prediction model in adult patients. *Artif Organs*. 2022.
- 544 26. Sy E, Sklar MC, Lequier L, Fan E, Kanji HD. Anticoagulation practices and the prevalence of major
545 bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation:
546 A systematic review and meta-analysis. *J Crit Care*. 2017;39:87-96.
- 547 27. Ruggeri L, Franco A, Alba AC, Lembo R, Frassoni S, Scandroglia AM, et al. Coagulation
548 Derangements in Patients With Refractory Cardiac Arrest Treated With Extracorporeal Cardiopulmonary
549 Resuscitation. *J Cardiothorac Vasc Anesth*. 2019;33(7):1877-82.
- 550 28. Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, et al. Factors associated with
551 outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. *Crit
552 Care*. 2013;17(2):R73.
- 553 29. Salomon B, Dasa V, Krause PC, Hall L, Chapple AG. Hospital Length of Stay Is Associated With
554 Increased Likelihood for Venous Thromboembolism After Total Joint Arthroplasty. *Arthroplast Today*.
555 2021;8:254-7 e1.
- 556 30. Agarwal G, Hajra A, Chakraborty S, Patel N, Biswas S, Adler MK, et al. Predictors and mortality
557 risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of
558 observational studies. *Ther Adv Cardiovasc Dis*. 2022;16:17539447221105013.

559 31. van Minnen O, van den Bergh WM, Droogh JM, Koehorst L, Lagrand WK, Raasveld SJ, et al.
560 Incidence and risk factors of deep vein thrombosis after extracorporeal life support. *Artif Organs*.
561 2022;46(9):1893-900.

562

563

564 1. **Figures**

565 Figure 1. Hematologic markers on arrival to the intensive care unit stratified by patients with and
566 without thrombosis and those with and without major bleeding.

567 Figure 2. Characteristics of major bleeding events. A. Sites of major bleeding. B. Percentage of
568 admitted patients who had a major bleeding event. C. Percentage of patients who had a major
569 bleeding event depending on admission fibrinogen level.

570 Figure 3. Characteristics of thrombotic events. A. Percentage of patients with different sites of
571 thrombosis with VTE(green) and arterial thrombosis (pink). B. Percentage of admitted patients
572 who present thrombosis per day of admission. * arterial thrombosis refers to aorta and/or SMA
573 thrombosis.

574 Figure 4. Central figure. Rates of bleeding and thrombosis. Multivariable model of risks of
575 bleeding and thrombosis. * denotes statistical significance.

576

577

578
579
580
581
582

2. Tables

Table 1. Demographics, baseline and arrest characteristics of patients with and without major bleeding and with and without a thrombotic event.

	Overall Cohort (N=200)	No major bleeding (N=65)	Major bleeding (N=135)	P value	No thrombotic events (N=153)	Thrombosis (N=47)	P value
<i>Baseline Characteristics</i>							
Gender, Male	162(81.0)	54(83.1)	108(80.0)	0.74	122(79.7)	40(85.1)	0.54
Age, years	57.0(12.2)	55.5(12.6)	57.7(11.9)	0.24	56.8(12.1)	57.8(12.5)	0.61
BMI, Kg/m ²	30.7(6.2)	30.2(25.9,35.4)	29.7(26.8,33.8)	0.73	29.7(26.8,33.7)	30.6(25.9,33.9)	0.99
<i>Comorbidities</i>							
Coronary artery disease	52(26.0)	14(21.5)	38(28.1)	0.41	38(24.8)	14(29.8)	0.62
Congestive Heart Failure	25(12.5)	6(9.2)	19(14.1)	0.48	18(11.8)	7(14.9)	0.77
Diabetes mellitus	49(24.5)	14(21.5)	35(25.9)	0.62	35(22.9)	14(29.8)	0.44
End stage renal disease	4(2.0)	1(1.5)	3(2.2)	1.00	3(2.0)	1(2.1)	1.00
Hyperlipidemia	49(24.5)	13(20.0)	36(26.7)	0.39	35(22.9)	14(29.8)	0.44
Hypertension	71(35.5)	17(26.2)	54(40.0)	0.08	49(32.0)	22(46.8)	0.09
<i>Arrest characteristics and treatments prior to ICU admission</i>							
CPR time, min	62(19)	61(19)	63(20)	0.84	62(20)	61(17)	0.69
IABP	142(71.0)	42(64.4)	100(74.1)	0.23	105(68.6)	37(78.7)	0.25
Heparin bolus during cannulation and PCI, Units	12578(4353)	12585(5202)	12575(3901)	0.99	12544(4588)	12682(3588)	0.85
Cangrelor	16(8.0)	3(4.6)	13(9.6)	0.34	11(7.2)	5(10.6)	0.65
GP iib/iiia inhibitor	6(3.0)	2(3.1)	4(3.0)	1.000	3(2.0)	3(6.4)	0.29
DAPT	124(62.0)	33(50.8)	91(67.4)	0.03	90(58.8)	34(72.3)	0.13
Ticagrelor	121(60.5)	33(50.8)	88(65.2)	0.11	87(56.9)	34(72.3)	0.08
Clopidogrel	3(1.5)	0(0.0)	3(2.2)	0.55	3(2.0)	0(0.0)	0.81

583 BMI, body mass index; CPR, cardiopulmonary resuscitation; DAPT, dual antiplatelet therapy;
584 IABP, intra-aortic balloon pump;

585

586 Table 2. Treatment characteristics and hospital course of patients who had a bleeding event and
587 those without bleeding events.

	Overall cohort (N=200)	No bleeding (N=65)	Major bleeding (N=135)	P value
<i>Transfusions during the hospitalization</i>				
Red blood cells, units	4.5(1.0,10.0)	1.0(0.0,2.0)	7.0(4.0,12.0)	<0.001
Platelets, units	1(0.0,4.0)	0.0(0.0,1.0)	2.0(0.0,5.0)	<0.001
Fresh Frozen Plasma, units	1.0(0.0,3.0)	0.0(0.0,0.0)	1.0(0.0,3.0)	<0.001
<i>Hospital Course</i>				
Renal Replacement Therapy, N(%)	55(27.5)	14(21.5)	41(30.4)	0.25
Days on continuous dialysis*(N=14)	6.0(4.0,18.0)	3.5(3.0,4.0)	8.0(4.0,20.0)	0.20
Thrombosis, N(%)	47(23.5)	11(16.9)	36(26.7)	0.16
Extubation, N(%)	53(26.5)	13(20.0)	40(29.6)	0.20
Days on mechanical ventilation** (N=53),	8.0(6.0,13.0)	6.0(5.0,8.0)	9.0(6.0,14.0)	0.05
Days on VA ECMO	4.0(3.0,5.0)	3.0(2.0,4.0)	4.0(2.0,5.0)	0.05
VA ECMO decannulation, N(%)	95(47.5)	21(32.3)	65(48.1)	0.19
Length of hospital stay, days	8.0(2.0,20.5)	4.0(2.0,14.0)	10.0(3.0,22.0)	0.01
Survival to hospital discharge, N(%)	64(32.0)	17(26.2)	47(34.8)	0.29

588 *calculated for patients who survived to discontinuation of continuous dialysis

589 **Including patients who survived to liberation from mechanical ventilation

590 Table 3. Treatment characteristics and hospital course of patients who had a thrombotic event
 591 including arterial thrombosis and VTE and those without thrombosis.

592


	No thrombosis (N=153)	Any Thrombosis (N=47)	P value	No arterial thrombi (N=169)	Arterial thrombosis (N=31)	P value	No VTE (N=178)	VTE (N=22)	P value
<i>Transfusions during the hospitalization</i>									
Red blood cells, units	4(1,9)	7(2,12)	0.01	4.0(1.0,9.0)	7.0(2.0,12.0)	0.05	4.0(1.0,9.3)	7.0(2.8,12.0)	0.07
Platelets, units	1.0(0.0,3.0)	2.0(0.0,5.0)	0.005	1.0(0.0,3.0)	2.0(0.0,6.0)	0.06	1.0(0.0,4.0)	2.0(1.0,5.5)	0.02
Fresh frozen	1(0,2)	0(0,2)	0.50	0(0,2)	1(1.3)	0.39	1(0,2)	0(0,1)	0.09

plasma, units									
<i>Hospital course</i>									
Renal Replacement Therapy	37(24.2)	18(38.3)	0.09	40(23.7)	15(48.4)	0.009	49(27.5)	6(27.3)	1.00
Days on continuous dialysis* (N=14)	4.5(2.8,11.3)	17.0(6.0,22.0)	0.12	5.0(3.0,18.0)	12.0(4.0,12.0)	0.39	5(3,12)	22(4,)	0.18
Major bleeding event	99(64.7)	36(76.6)	0.18	111(65.7)	24(77.4)	0.28	118(66.3)	17(77.3)	0.42
Extubation, N(%)	37(24.2)	16(34.0)	0.25	48(28.4)	5(16.1)	0.23	39(21.9)	14(63.6)	<0.001
Days on mechanical ventilation* * (N=53), N(%)	7.0(5.5,11.0)	11.5(6.5,18.5)	0.07	7.5(6.0,13.0)	13.0(8.0,17.0)	0.17	7.0(6.0,11.0)	11.5(7.5,15.5)	0.09
VA ECMO decannulation, N(%)	60(39.2)	26(55.3)	0.07	73(43.1)	13(41.9)	1.00	68(38.2)	18(81.8)	<0.001
Length of VA ECMO run days	3.5(2.4)	4.8(3.1)	0.008	3.6(2.5)	4.9(3.1)	0.04	3.7(2.6)	4.8(2.9)	0.12
Length of hospital stay, days	6(2,18)	15(5,29)	<0.001	8(2,21)	10(3,22)	0.37	6.0(2.0,17.3)	28.0(15.0,37.8)	<0.001
Survival to hospital discharge, N(%)	46(30.1)	18(38.3)	0.38	58(34.3)	6(19.4)	0.15	49(27.5)	15(68.2)	<0.001

593


594

595 Figure 1. Hematologic markers on arrival to the intensive care unit stratified by patients
 596 with and without thrombosis and those with and without major bleeding.



598


599 Figure 2. Characteristics of major bleeding events. A. Sites of major bleeding. B. Percentage of
600 admitted patients who had a major bleeding event. C. Percentage of patients who had a major
601 bleeding event depending on admission fibrinogen level.



602

603 Figure 3. Characteristics of thrombotic events. A. Percentage of patients with different sites of
604 thrombosis with VTE(green) and arterial thrombosis (pink). B. Percentage of admitted patients
605 who present thrombosis per day of admission. * arterial thrombosis refers to aorta and/or SMA
606 thrombosis.

607



608


609

610

611

612 Figure 4. Central figure. Rates of bleeding and thrombosis. Multivariable model of risks of
 613 bleeding and thrombosis. * denotes statistical significance.

614
 615



616
 617
 618
 619